Robert W. Baird analyst Jeff Johnson maintained a Buy rating on Dexcom (NASDAQ:DXCM) on Tuesday, setting a price target of $460, which is approximately 17.96% above the present...
Robert W. Baird analyst Jeff Johnson maintained a Buy rating on Dexcom (NASDAQ:DXCM) on Thursday, setting a price target of $460, which is approximately 20.13% above the present...
Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Dexcom (NASDAQ:DXCM) on Thursday, setting a price target of $485, which is approximately 25.62% above the...
The earnings per share (EPS) for all S&P 500 companies combined increased last week from $171.33 to $173.12. The forward EPS has now grown 8.87% since January 1st.Companies...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,402.22 | 2,432.06 | 2,400.30 | -32.65 | -1.34% | 2.31M | NASDAQ | |||
| 22.58 | 22.79 | 22.52 | -0.23 | -1.01% | 102.34K | NYSE | |||
| 2.91 | 2.95 | 2.88 | -0.07 | -2.35% | 449.81K | NYSE | |||
| 13.28 | 14.00 | 13.26 | -0.28 | -2.06% | 5.25M | NYSE | |||
| 329.66 | 336.15 | 329.00 | -6.85 | -2.04% | 23.04M | NASDAQ | |||
| 17.01 | 17.27 | 16.98 | -0.24 | -1.39% | 1.01M | NYSE | |||
| 19.01 | 19.01 | 19.00 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 78.85 | 81.73 | 78.63 | -3.93 | -4.75% | 6.11M | NYSE | |||
| 59.26 | 64.96 | 56.85 | -1.47 | -2.42% | 243.65M | NYSE | |||
| 8.74 | 9.05 | 8.63 | -0.46 | -5.00% | 16.89M | NYSE | |||
| 212.30 | 213.84 | 210.59 | +0.70 | +0.33% | 13.72M | NYSE | |||
| 239.26 | 242.60 | 232.42 | +7.10 | +3.06% | 4.43M | NASDAQ | |||
| 46.91 | 48.37 | 46.59 | -0.45 | -0.95% | 90.78M | NYSE | |||
| 17.24 | 17.31 | 16.87 | -0.13 | -0.75% | 87.21K | NASDAQ | |||
| 76.43 | 77.16 | 76.16 | -1.35 | -1.74% | 6.31M | NYSE |
Dexcom, Inc. is a medical device company. The Company is primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers. Its products include Dexcom G6 and Dexcom Share. The G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an app on the patient’s iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients, who can remotely monitor a patient’s glucose information and receive alert notifications.
